Financial Results for Q1 FY27 (Quarter ended 30th June, 2026)

The Board approved the unaudited financial results for the quarter ended 30th June, 2026:

Revenue Performance:

  • Revenue from operations: ₹19,381.04 lakh (compared to ₹18,647.94 lakh in Q1 FY26, showing 3.9% YoY growth)
  • Other income: ₹307.67 lakh (compared to ₹338.84 lakh in Q1 FY26)
  • Total revenue: ₹19,688.71 lakh

Expense Breakdown:

  • Cost of materials consumed: ₹15,996.42 lakh
  • Purchases of Stock-in-Trade: ₹414.33 lakh
  • Changes in inventories: (₹1,579.88) lakh
  • Employee benefits expense: ₹735.16 lakh
  • Finance costs: ₹0.35 lakh
  • Depreciation and amortization: ₹243.28 lakh
  • Other expenses: ₹2,186.24 lakh
  • Total expenses: ₹17,995.90 lakh

Profitability Metrics:

  • Profit before tax: ₹1,692.81 lakh (compared to ₹1,095.31 lakh in Q1 FY26, showing 54.5% growth)
  • Tax expenses: ₹550.32 lakh (Current tax: ₹413.20 lakh, Deferred tax: ₹137.12 lakh)
  • Profit after tax: ₹1,142.49 lakh (compared to ₹830.12 lakh in Q1 FY26, showing 37.6% growth)
  • Total comprehensive income: ₹1,139.20 lakh

Per Share Data:

  • Basic EPS: ₹1.14
  • Diluted EPS: ₹1.14
  • Paid-up equity share capital: ₹5,011.20 lakh (Face value ₹5 each)

Other Financial Indicators:

  • EBITDA: ₹1,936.44 lakh (9.99% margin)
  • Adjusted EBITDA (excluding FOREX gain/loss and other income): ₹1,814.45 lakh (9.36% margin)

Promoter Group Reclassification Withdrawal

The Board approved withdrawal requests from three promoter group members who sought to withdraw their applications for reclassification from promoter to public category:

| Name | Shares Held | % Holding |

| Vikram Kirtilal Shah | 200 | 0.00% |

| Kiran Piyush Shah | 15,388 | 0.02% |

| Kinjal Siddharth Jhaveri | 816,160 | 0.81% |

| Total | 831,748 | 0.83% |

All three individuals submitted formal withdrawal letters dated 06th August 2026, confirming they will continue as promoter group members.

Policy Adoption

The Board adopted a revised Policy on Related Party Transactions, which is available on the company's website at www.anuhpharma.com.

Meeting Details

The Board meeting commenced at 1:00 PM and concluded at 5:15 PM on 07th August 2026.

Auditor Review

The financial results were subjected to limited review by the statutory auditors, Jayantilal Thakkar & Co., who concluded that nothing came to their attention suggesting material misstatement.

Capital Structure Impact

The financial results reflect the effect of a 1:1 bonus share issuance completed on 16th July 2025, which increased the paid-up capital from ₹2,505.60 lakh to ₹5,011.20 lakh.

Segment Information

The company operates only in the Bulk Drug and Chemicals segment, which is its primary reportable segment.